Aktiia
Aktiia is a privately held company founded in 2018, specializing in AI-driven solutions for hypertension management and digital therapeutics. Based in Neuchatel, Switzerland, Aktiia offers a CE-marked platform and has conducted over 20 clinical trials, utilizing extensive data to enhance patient care in blood pressure monitoring.
Company Overview
Founded in 2018, Aktiia is a privately held small business based in Neuchatel, Switzerland. The company operates in the Hospitals and Health Care industry, specializing in AI-driven insights for the understanding and management of hypertension. With a team size of 53, Aktiia focuses on digital therapeutics, patient management, and blood pressure monitoring.
Products and Services
Aktiia offers a CE-marked platform that includes a blood pressure monitoring app and wearable devices. The platform provides real-time visualization of metrics such as blood pressure Time in Target Range (TTR). The optical blood pressure monitoring technology is validated for accuracy across multiple body positions and does not require calibration with a regular cuff.
Clinical Research and Validation
Aktiia has conducted over 20 clinical trials worldwide and has validated its technology in six clinical studies. The company's wearable blood pressure monitor has been featured in Nature Scientific Reports for its accuracy. The company utilizes over 300 million data points from more than 60,000 active users to enhance hypertension comprehension.
Market Presence
Aktiia's platform is available in seven European markets and has over 80,000 customers across these regions. The company plans to enter the US market in 2025. It has achieved regulatory approval as a medical device in 44 countries worldwide, classified as a Class IIa Medical Device under the EU Medical Device Regulation.
Technology and Innovation
Aktiia employs AI-powered algorithms to create multidimensional representations of blood pressure and heart rate data. Since its commercial launch in 2021, the company has gathered over 10 billion data points from users globally, contributing to its innovative approach to hypertension management.